CSPC SYH2056 FDA Approval Targets Depression with 5-HT2A Agonist
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056 tablets, a Category 1 chemical drug, has...
HKG: 1093
CSPC’s SYH2056 Wins NMPA Nod for Depression Trials as Fast‑Acting 5‑HT2A Agonist
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056, a selective 5‑HT2A receptor agonist, received...
CSPC’s SYH2061 Injection Receives NMPA Clinical‑Trial Approval for IgA Nephropathy
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class 1 chemical novel drug...
CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...
CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management
CSPC Pharmaceutical Group Limited (HKG: 1093) today announced that the National Medical Products Administration (NMPA)...
CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the National Medical Products Administration (NMPA) has...
CSPC’s ALMB-0166 Approved for Phase II Trials in Parkinson’s Disease
CSPC Pharmaceutical Group Limited (HKG: 1093), a China-based company, announced on September 15, 2025, that...
CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small‑molecule, SYH2066, has been...
CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced today that Anbenitamab Antibody Injection (KN026), co‑developed with Alphamab...
CSPC Pharmaceutical’s Semaglutide Injection NMPA Marketing Application Accepted
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its semaglutide...
CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced today that it has entered into an...
Alphamab Oncology’s JSKN003 Granted FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer
China-based Alphamab Oncology (HKG: 9966) announced today that its drug candidate JSKN003 has received Orphan...
CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...
Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio
China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of...
AstraZeneca and CSPC Pharma Collaborate on Novel Oral Drug Discovery
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CSPC Pharmaceutical Group Ltd (HKG: 1093)...
CSPC Pharma’s SYS6040 ADC Gains FDA Clinical Trial Approval
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...
CSPC Pharmaceutical’s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough...
CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...
Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke
Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...